Generic drugmaker admits to price-fixing popular cholesterol drug

Apotex, a generic drugmaker based in Weston, Fla., admitted to fixing prices for a commonly prescribed cholesterol drug and agreed to pay $24.1 million to resolve charges. 

The charges claim Apotex worked with other drug companies to increase and maintain the price of pravastatin, a cholesterol drug that lowers the risk of heart disease and stroke, from 2013 to 2015. 

Apotex agreed to pay $24.1 million as part of a deferred prosecution agreement. Under the agreement, Apotex is required to cooperate with the government's broader investigation into generic drug pricing and put in place a program to detect and prevent future antitrust violations. 

In return, the Justice Department will defer any prosecution for three years and drop the price-fixing charge if Apotex cooperates. 

Read the full news release here

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like

Thank you so much for your interest in our content. Please register to access this complimentary archived content. By registering, you will receive our newsletter which can be opted out of at any time.

 

 

Already Registered? Click here to confirm.